Cargando…
A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy
BACKGROUND: Patient-derived orthotopic xenograft (PDOX) is a popular animal model for translational cancer research. Immunotherapy is a promising therapy against glioblastoma (GBM). However, the PDOX model is limited to evaluating immune-related events. Our study aims to establish GBM humanized PDOX...
Autores principales: | Xu, Shengchao, Yan, Xi, Dai, Gan, Luo, Chengke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222697/ https://www.ncbi.nlm.nih.gov/pubmed/34178691 http://dx.doi.org/10.3389/fonc.2021.692403 |
Ejemplares similares
-
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018) -
A novel gene signature predicts chemoradiotherapy efficacy and tumor immunity in high‐grade glioma
por: Xu, Shengchao, et al.
Publicado: (2020) -
Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer
por: Zhang, Hongsheng, et al.
Publicado: (2023) -
A Nanoparticle-Conjugated Anti-TBK1 siRNA Induces Autophagy-Related Apoptosis and Enhances cGAS-STING Pathway in GBM Cells
por: Xu, Shengchao, et al.
Publicado: (2021) -
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)